Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients

被引：15

作者：

Xu, L. ^{[1
]}

Anderson, J. ^{[2
]}

Ferns, B. ^{[3
]}

Cook, P. ^{[1
]}

Wildfire, A. ^{[4
]}

Workman, J. ^{[1
]}

Graham, S. ^{[1
]}

Smit, E. ^{[1
]}

机构：

[1] Birmingham Heartlands & Solihull NHS Trust, W Midlands Publ Hlth Lab, Hlth Protect Agcy, Birmingham B9 5SS, W Midlands, England

[2] Homerton Univ Hosp NHS Fdn Trust, London, England

[3] UCL, London, England

[4] Chelsea Westminster Hosp, London, England

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2008年 / 24卷 / 07期

关键词：

D O I：

10.1089/aid.2007.0303

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Two potent integrase inhibitors (IN-Is), raltegravir (RAL, MK-0518) and elvitegravir (EGV, GS-9137), have been shown to be potent inhibitors for HIV-1 and resistance mutations have been identified in HIV-1 clinical trials. In this study, sequences from 11 HIV-2 patients were examined for IN polymorphisms. The primary mutations associated with RAL and EGV resistance were not detected despite the genetic variability among clinical isolates. Our study provides basic information on genotypic susceptibility of HIV-2 to RAL and EGV and supports the suggestion that RAL and EGV could be considered as a new therapeutic option for treating HIV-2-infected patients.

引用

页码：1003 / 1007

页数：5

共 50 条

[1] Agenerase™ shows promise in treatment-naive and treatment-experienced HIV patients
不详
[J]. AIDS PATIENT CARE AND STDS, 1999, 13 (02) : 128 - 129
[2] Pharmacokinetics of Sifuvirtide in Treatment-Naive and Treatment-Experienced HIV-Infected Patients
Meng, Qingfang
Dong, Tianhao
Chen, Xin
Tong, Baohui
Qian, Xiaohong
Che, Jinjing
Cheng, Yuanguo
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (12) : 4038 - 4047
[3] HIV Integrase Polymorphisms in Treatment-Naive and Treatment-Experienced HIV-Infected Patients in Thailand Where HIV Subtype A/E Predominates
Phuphuakrat, A.
[J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A113 - A113
[4] HIV Type 1 Integrase Polymorphisms in Treatment-Naive and Treatment-Experienced HIV Type 1-Infected Patients in Thailand Where HIV Type 1 Subtype A/E Predominates
Phuphuakrat, Angsana
Pasomsub, Ekawat
Kiertiburanakul, Sasisopin
Chantratita, Wasun
Sungkanuparph, Somnuek
[J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2012, 28 (08) : 937 - 943
[5] Optimizing management of treatment-naive and treatment-experienced HIV+ patients: the role of maraviroc
Poveda, Eva
Soriano, Vincent
[J]. HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2010, 2 : 51 - 58
[6] HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients
Archampong, Timothy Na
Boyce, Ceejay L.
Lartey, Margaret
Sagoe, Kwamena W.
Obo-Akwa, Adjoa
Kenu, Ernest
Blackard, Jason T.
Kwara, Awewura
[J]. ANTIVIRAL THERAPY, 2017, 22 (01) : 13 - 20
[7] HIV MODEL INCORPORATING DIFFERENTIAL PROGRESSION FOR TREATMENT-NAIVE AND TREATMENT-EXPERIENCED INFECTIVES
Chigidi, Esther
Lungu, Edward M.
[J]. MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2009, 6 (03) : 427 - 450
[8] HIV integrase variability and genetic barrier in antiretroviral naive and experienced patients
Piralla, Antonio
Paolucci, Stefania
Gulminetti, Roberto
Comolli, Giuditta
Baldanti, Fausto
[J]. VIROLOGY JOURNAL, 2011, 8
[9] Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naive and Treatment-Experienced HIV Patients in South Korea
Jeong, Wooyong
Jung, In Young
Choi, Heun
Kim, Jung Ho
Seong, Hye
Ahn, Jin Young
Jeong, Su Jin
Ku, Nam Su
Kim, June Myung
Choi, Jun Yong
[J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2019, 35 (02) : 213 - 216
[10] Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada
Despiégel N.
Anger D.
Martin M.
Monga N.
Cui Q.
Rocchi A.
Pulgar S.
Gilchrist K.
Refoios Camejo R.
[J]. Infectious Diseases and Therapy, 2015, 4 (3) : 337 - 353

← 1 2 3 4 5 →